A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2017
Price : $35 *
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Fibromyalgia
- Focus Adverse reactions
- Acronyms BESTFIT-OLE
- Sponsors Tonix Pharmaceuticals Inc
- 23 Oct 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 08 Jan 2014 New trial record
- 10 Dec 2013 Tonix Pharmaceuticals announced the enrolment of completers from the BESTFIT trial into a 12-month open-label extension study.